Development of a quantitative flow cytometry-based assay to assess infection by Plasmodium falciparum sporozoites.

Molecular and Biochemical Parasitology
Alexis KaushanskyStefan H I Kappe

Abstract

The human malaria parasite Plasmodium falciparum causes the most deadly parasitic disease worldwide, necessitating the development of interventions that block infection. Yet, preclinical assays to measure inhibition of infection date from the 1980s and are based on microscopy. Here, we describe the development of a simple flow cytometric assay that can be used to quantitatively assess P. falciparum sporozoite infection in vitro in low and medium throughput. We demonstrate the utility of this assay for assessing both drug inhibition of infection and measuring efficacy of antibodies in blocking parasite infection. This methodology will aid in assessing functional antibody responses to vaccination and novel drugs that prevent mosquito-to-man transmission of malaria.

References

Apr 4, 2002·The Journal of Infectious Diseases·Stephen L HoffmanThomas L Richie
Jan 4, 2008·Proceedings of the National Academy of Sciences of the United States of America·Alice S TarunStefan H I Kappe
Jan 8, 2008·Lancet·M D Cappellini, G Fiorelli
Feb 5, 2008·Molecular and Biochemical Parasitology·Sebastian A MikolajczakStefan H I Kappe
Sep 10, 2008·Cell Host & Microbe·Ashley M VaughanStefan H I Kappe
Oct 20, 2011·The New England Journal of Medicine·UNKNOWN RTS,S Clinical Trials PartnershipPreeti Vansadia

❮ Previous
Next ❯

Citations

Dec 19, 2012·Malaria Journal·Mark KennedyScott E Lindner
May 16, 2014·Molecular Therapy : the Journal of the American Society of Gene Therapy·Sebastian A MikolajczakStefan H I Kappe
Mar 13, 2014·Cellular Microbiology·Laura S AustinStefan H I Kappe
Oct 29, 2015·Journal of Ultrasound in Medicine : Official Journal of the American Institute of Ultrasound in Medicine·Shane ArishenkoffGraydon S Meneilly
Jun 25, 2014·Journal of Ultrasound in Medicine : Official Journal of the American Institute of Ultrasound in Medicine·Mitchell LeeGraydon S Meneilly
Jul 10, 2013·Current Protocols in Cytometry·Howard M ShapiroBrian T Grimberg
Nov 25, 2016·Clinical and Vaccine Immunology : CVI·Ryan W J SteelStefan H I Kappe
Aug 27, 2014·Infection and Immunity·Anke HarupaStefan H I Kappe
Aug 14, 2019·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Jane AchanUmberto D'Alessandro
May 5, 2018·Frontiers in Immunology·Nana K MinkahStefan H I Kappe
Jun 25, 2019·Frontiers in Immunology·Yun Shan GohLaurent Rénia
Jan 6, 2017·Science Translational Medicine·James G KublinStefan H I Kappe
Jan 28, 2021·Expert Review of Vaccines·Danielle I Stanisic, Matthew B B McCall

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antimalarial Agents (ASM)

Antimalarial agents, also known as antimalarials, are designed to prevent or cure malaria. Discover the latest research on antimalarial agents here.

Antimalarial Agents

Antimalarial agents, also known as antimalarials, are designed to prevent or cure malaria. Discover the latest research on antimalarial agents here.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.